Re: Long-Term Safety, Tolerability and Efficacy of Flexible-Dose Fesoterodine in Elderly Patients with Overactive Bladder: Open-Label Extension of the SOFIA Trial Editorial Comment

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2014年 / 192卷 / 06期
关键词：
D O I：
10.1016/j.juro.2014.09.064
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1766 / 1766
页数：1
相关论文
共 50 条
  • [1] Long-Term Safety, Tolerability and Efficacy of Flexible-Dose Fesoterodine in Elderly Patients With Overactive Bladder: Open-Label Extension of the SOFIA Trial
    Wagg, Adrian
    Khullar, Vik
    Michel, Martin C.
    Oelke, Matthias
    Darekar, Amanda
    Bitoun, Caty Ebel
    NEUROUROLOGY AND URODYNAMICS, 2014, 33 (01) : 106 - 114
  • [2] Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by AgePooled Analysis of Two Open-Label Extension Studies
    Peter K. Sand
    John Heesakkers
    Stephen R. Kraus
    Martin Carlsson
    Zhonghong Guan
    Sandra Berriman
    Drugs & Aging, 2012, 29 : 119 - 131
  • [3] Long-Term Safety, Tolerability and Efficacy of Fesoterodine in Subjects with Overactive Bladder Symptoms Stratified by Age Pooled Analysis of Two Open-Label Extension Studies
    Sand, Peter K.
    Heesakkers, John
    Kraus, Stephen R.
    Carlsson, Martin
    Guan, Zhonghong
    Berriman, Sandra
    DRUGS & AGING, 2012, 29 (02) : 119 - 131
  • [4] Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
    Wyndaele, J. -J.
    Goldfischer, E. R.
    Morrow, J. D.
    Gong, J.
    Tseng, L. -J.
    Guan, Z.
    Choo, M. -S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (04) : 560 - 567
  • [5] Patient-Optimized Doses of Fesoterodine Improve Bladder Symptoms in an Open-Label, Flexible-Dose Study Editorial Comment
    Kaplan, Steven A.
    JOURNAL OF UROLOGY, 2011, 186 (03): : 994 - 995
  • [6] Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial
    McConville, B
    Carrero, L
    Sweitzer, D
    Potter, L
    Chaney, R
    Foster, K
    Sorter, M
    Friedman, L
    Browne, K
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) : 75 - 82
  • [7] Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms
    Van Kerrebroeck, P. E. V.
    Heesakkers, J.
    Berriman, S.
    Aiyer, L. Padmanabhan
    Carlsson, M.
    Guan, Z.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 584 - 593
  • [8] Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms
    Scarpero, Harriette
    Sand, Peter K.
    Kelleher, Con J.
    Berriman, Sandra
    Bavendam, Tamara
    Carlsson, Martin
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 921 - 930
  • [9] Re: Efficacy and Safety of Fesoterodine Treatment for Overactive Bladder Symptoms in Elderly Women with and without Hypertension Editorial Comment
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2019, 201 (03): : 420 - 421
  • [10] Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: Analysis of results from a 2-year, open-label extension study
    Dwyer, P.
    Lheritier, K.
    Steel, M.
    NEUROUROLOGY AND URODYNAMICS, 2006, 25 (06) : 657 - 658
12345